News | Endovascular Aortic Repair | May 23, 2017

New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair

Prospective, nonrandomized study evaluates endovascular repair of pararenal and thoracoabdominal aortic aneurysm using fenestrated-branched endografts based on supraceliac sealing zones

New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair

May 23, 2017 — Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and branched-graft devices, based on a report of prospectively studied patients with complex aortic aneurysm in the May edition of the Journal of Vascular Surgery.

Mayo Clinic researchers led by vascular surgeon Gustavo Oderich, M.D., reported no early mortality, need for permanent dialysis or open conversion, and two patients with paraplegia in their series of 127 patients (including 80 thoracoabdominal aneurysms).

At a follow-up averaging nine months, they had no ruptures or sac enlargement, but there was an 18 percent need for endovascular re-intervention.

Aortic aneurysm remains a significant cause of mortality and morbidity, particularly in aging patients. While most aneurysms involve the abdominal portion of the aorta (abdominal aortic aneurysm, or AAA), some develop aneurysmal degeneration more proximally involving the paravisceral and thoracic aorta. Repair of these aneurysms, traditionally performed by open surgical approaches, is considerably more complex with increased rates of death, dialysis and paraplegia following repair.

Endovascular therapies for more proximal aortic aneurysm are evolving and mainly involve the use of fenestrated and branched-graft designs. Complications specific to endovascular repair include loss of branch vessel patency (either intra-operative or in follow-up) and endoleak.  It is hoped that collaboration between the advanced vascular surgical teams performing these highly complex procedures and companies developing the products used for implantation will continue to drive success for patients with aortic aneurysm.

While these results are outstanding compared to open surgical treatment, Oderich noted that, “Follow-up is still too short to draw any conclusions about time-dependent outcomes, and it is likely that rates of reinterventions, vessel patency and endoleaks will be affected during longer follow-up.” 

For more information: www.jvascsurg.org

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now